Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DNMT1 | P26358 | 1/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.42 |
| ▸ | MEN1 | O00255 | 2/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.42 |
| ▸ | LMNA | P02545 | 2/20 | 0.42 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.42 |
| ▸ | USP2 | O75604 | 1/20 | 0.42 |
| ▸ | TP53 | P04637 | 1/20 | 0.42 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.42 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.42 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.42 |
| ▸ | HPGD | P15428 | 1/20 | 0.42 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.42 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.42 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.42 |
| ▸ | MAPT | P10636 | 2/20 | 0.41 |
| ▸ | POLB | P06746 | 1/20 | 0.41 |
| ▸ | RAB9A | P51151 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.41 |
| ▸ | CES1 | P23141 | 3/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL567138 | 0.78 | DNMT1 (0.50) | DNMT1ALDH1A1MEN1KMT2ALMNA | |
| SCHEMBL6734024 | 0.78 | DNMT1 (0.50) | DNMT1ALDH1A1MEN1KMT2ALMNA | |
| SCHEMBL8407062 | 0.78 | DNMT1 (0.50) | DNMT1ALDH1A1MEN1KMT2ALMNA | |
| SCHEMBL10426593 | 0.78 | DNMT1 (0.50) | DNMT1ALDH1A1MEN1KMT2ALMNA | |
| SCHEMBL4109839 | 0.78 | DNMT1 (0.50) | DNMT1ALDH1A1MEN1KMT2ALMNA | |
| SCHEMBL43564 | 0.76 | DNMT1 (0.49) | DNMT1ALDH1A1MEN1KMT2ALMNA | |
| SCHEMBL299840 | 0.75 | HSPA1A (0.56) | DNMT1ALDH1A1MEN1KMT2ALMNA | |
| SCHEMBL12235635 | 0.74 | CYP1B1 (0.53) | DNMT1ALDH1A1MEN1KMT2ALMNA | |
| SCHEMBL10795639 | 0.74 | DNMT1 (0.46) | DNMT1ALDH1A1MEN1KMT2ALMNA | |
| SCHEMBL9327695 | 0.74 | DNMT1 (0.46) | DNMT1ALDH1A1MEN1KMT2ALMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0930883-B1 | NEUROTROPHIN ANTAGONISTS FOR THE TREATMENT OF EPILEPSY, ALZHEIMER'S DISEASE AND PAIN | ALLELIX BIOPHARMA (CA) | 2006-01-11 | — | — | EP | claimed |
| US-20050250807-A1 | Neurotrophin antagonist compositions | TEHIM ASHOK | 2005-11-10 | — | — | US | claimed |
| US-20020169182-A1 | Neurotrophin antagonist compositions | ALLELIX BIOPHARMACEUTICALS INC. (CA) | 2002-11-14 | — | — | US | claimed |
| EP-0930883-A1 | NEUROTROPHIN ANTAGONIST COMPOSITIONS | Allelix Biopharmaceuticals Inc. (CA) | 1999-07-28 | — | — | EP | claimed |
| WO-1998017278-A1 | NEUROTROPHIN ANTAGONIST COMPOSITIONS | ALLELIX BIOPHARMACEUTICALS INC. (CA) | 1998-04-30 | — | — | WO | claimed |
| US-20090215815-A1 | Neurotrophin antagonist compositions | PAINCEPTOR PHARMA CORPORATION (CA) | 2009-08-27 | — | — | US | disclosed |
| US-20080287484-A1 | Neurotrophin antagonist compositions | TEHIM ASHOK | 2008-11-20 | — | — | US | disclosed |
| US-7291629-B2 | Neurotrophin antagonist compositions | PAINCEPTOR PHARMA CORPORATION (CA) | 2007-11-06 | — | — | US | disclosed |
| EP-0930883-B1 | NEUROTROPHIN ANTAGONISTS FOR THE TREATMENT OF EPILEPSY, ALZHEIMER'S DISEASE AND PAIN | ALLELIX BIOPHARMA (CA) | 2006-01-11 | — | — | EP | disclosed |
| US-20050250807-A1 | Neurotrophin antagonist compositions | TEHIM ASHOK | 2005-11-10 | — | — | US | disclosed |
| US-20020169182-A1 | Neurotrophin antagonist compositions | ALLELIX BIOPHARMACEUTICALS INC. (CA) | 2002-11-14 | — | — | US | disclosed |
| EP-0930883-A1 | NEUROTROPHIN ANTAGONIST COMPOSITIONS | Allelix Biopharmaceuticals Inc. (CA) | 1999-07-28 | — | — | EP | disclosed |
| WO-1998017278-A1 | NEUROTROPHIN ANTAGONIST COMPOSITIONS | ALLELIX BIOPHARMACEUTICALS INC. (CA) | 1998-04-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090215815-A1 | Neurotrophin antagonist compositions | NGF, NTRK2, BDNF | DNMT1 4820/4885ALDH1A1 1561/4885MEN1 4269/4885 |
| US-20050250807-A1 | Neurotrophin antagonist compositions | NGF, NTRK2, BDNF | DNMT1 4837/4885ALDH1A1 1739/4885MEN1 4175/4885 |
| US-20020169182-A1 | Neurotrophin antagonist compositions | NTRK2, NGF, BDNF | DNMT1 4872/4885ALDH1A1 1523/4885MEN1 4752/4885 |
| US-20080287484-A1 | Neurotrophin antagonist compositions | NGF, NTRK2, BDNF | DNMT1 4826/4885ALDH1A1 1866/4885MEN1 4146/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.